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sided medical tape and used to determine each of the three test angles.
Participants were ﬁrst shown one of the angles, which was held for a few
seconds, then were asked to close their eyes and attempt to reproduce the
angle; this was repeated for all three test angles. We also repeated these
assessments at 24 and 48 weeks to test durability of response. The mean
error (absolute angle error) between the actual and replicated angles was
calculated for each of the three test angles. The Tai Chi and control groups
were compared by intention-to-treat using t-tests.
Results: The participants had a mean age of 65y (SD 7.8), mean disease
duration 10y (SD 7.6), mean BMI 30.0 kg/m2 (SD 4.8), and median K/L
grade 4; 75% were female, 70% were white. There were no signiﬁcant
differences at baseline in demographics, radiographic score, and outcome
measures. Attendance rate was 85% in the Tai Chi versus 89% in the
attention control. Participants in the Tai Chi arm exhibited signiﬁcantly
improved proprioception at 30 degrees, but not at 45 and 60 degrees, at
12 weeks (Table 1). Patients who continued Tai Chi practice after 12 weeks
also reported no signiﬁcant improvements in knee proprioception at 24
and 48 weeks.
Conclusion: We were not able to demonstrate in this pilot study that
Tai Chi is beneﬁcial for knee proprioception in people with severe KOA.
Potential confounders of the test including baseline characteristics, knee
pain severity, effusion and function, modiﬁed Tai Chi style, changes in joint
position and body weight, small sample size may limit data interpretation
and evaluation of the results. Standardized and reproducible measures for
knee proprioception should be explored in the future research.
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EFFECTS OF NAPROXCINOD AND NAPROXEN ON CHANGE IN JOINT SPACE
WIDTH IN THE TIBIO-FEMORAL JOINT: RESULTS OF A 52-WEEK,
RANDOMIZED CONTROLLED TRIAL
M.C. Hochberg1, T.J. Schnitzer2, C.E. Marrero3, F. Berembaum4,
B. Duquesroix5, H. Frayssinet5
1Univ. of Maryland Sch. of Med., Baltimore, MD; 2Northwestern Univ., Chicago,
IL; 3Louisiana State Univ. Hlth.Sci. Ctr., New Orleans, LA; 4Hosp. Saint-Antoine,
Paris, France; 5NicOx, Inc, Sophia-Antipolis, France
Purpose: In previous studies, naproxcinod, a novel cyclooxygenase inhibit-
ing nitric oxide donator (CINOD), has shown eﬃcacy similar to naproxen
in the treatment of the signs and symptoms of hip and knee osteoarthritis
(OA), but with effects on blood pressure (BP) similar to placebo. The
objective of this analysis is to determine if nitric oxide donation from
naproxcinod contributes to any difference in change in joint space width in
the tibio-femoral joint over one year compared to naproxen.
Methods: Data were analyzed from a 53-week, randomized, double-blind,
parallel-group clinical trial of 1020 patients with idiopathic knee OA who
were randomized to naproxcinod 750 mg, naproxcinod 375 mg, naproxen
500 mg or placebo (all bid) for 13 weeks; patients who had received
placebo were then re-randomized to naproxcinod either 750 mg or 375 mg
bid. Weight-bearing posterior-anterior (PA) radiographs were obtained in
the semiﬂexed position with a standard protocol by radiology technicians
using the SynaFlexer™ positioning device at baseline (between 4 and
10 days prior to randomization) and after 52 weeks in patients who
completed the study. All images (either hard copy or digital) were sent to
Synarc Inc. (San Francisco, CA) for quality assessment. A single trained and
certiﬁed radiologist measured minimum joint space width (JSW) using a
semiautomatic computer program on digitized images that were paired by
subject but randomized and blinded to time sequence. Mean (SD) change
in minimum JSW by compartment in the index knee was calculated for
each treatment group. No statistical comparisons were performed of this
exploratory safety endpoint.
Results: A total of 1020 patients with idiopathic knee OA were enrolled in
the study and randomized to one of the four treatment groups: mean (SD)
Table 1
All in Millimeters Naproxcinod 750 Naproxcinod 375 Naproxen 500
Medial compartment
Mean change (SD) 0.130 (0.92) -0.064 (0.812) 0.118 (1.18)
Median change (min, max) 0.00 (-2.06, 3.79) -0.01 (-4.22, 1.98) 0.00 (-3.73, 6.87)
Lateral compartment
Mean change (SD) -0.109 (1.23) -0.145 (0.98) -0.153 (1.22)
Median change (min, max) -0.06 (-5.58, 3.50) -0.02 (-3.66, 2.00) -0.08 (-6.15, 3.24)
age 59.8 (9.8) years, 709 (71%) women, 789 (79%) white, mean BMI 33.8
kg/m2. A total of 391 subjects completed 52 weeks on study medication
and had paired knee x-rays that were read for minimum JSW at both time
points. Mean and median changes in minimum JSW in both the medial and
lateral compartments are shown in Table 1.
Conclusions: These data show no signiﬁcant difference in JSW change for
naproxcinod as compared to naproxen over one year. Changes in minimum
JSW seen in this study were consistent with data reported in published
literature for patients with knee OA.
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M. Woodward2
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Purpose: To determine the association between knee pain and physical
function (last 48 hours) and health related quality of life (past 4 weeks) and
prospective reporting of knee pain and global assessment of knee OA over
the following seven day period in a cohort of people with symptomatic
knee osteoarthritis participating in the two year Long-term Evaluation of
Glucosamine Sulphate (LEGS) study.
Methods: The LEGS study is a 2×2 factorial design randomised placebo-
controlled clinical trial allocating participants to glucosamine sulphate
(1500mg) and chondroitin sulphate (800mg) or matching placebo for two
years. Participants are required to attend annual clinic assessments (includ-
ing WOMAC and SF-12 questionnaires) and complete a 7-day Participant
Diary collecting daily prospective data on knee pain (At its worst, how
much pain did you have in your knee today? 0-10 (No pain to worst
pain) and a global assessment (Considering all the ways your knee arthritis
affects you, how would you say your knees are today? Excellent to Poor).
For each participant both the average knee pain score and the highest score
reported over 7 days was extrapolated for analysis. For each scale, apart
from the SF-12, higher scores indicate more pain or disability.
Results: A total of 605 people with mild to moderate symptomatic knee
OA were randomised (October 2007-2009) and completed the baseline
clinic assessment and the immediately following 7-day Participant Diary
reporting (Table 1).
Table 1. Baseline pain and disability
Clinic Assessment Mean (sd)
Age 60.3 (8.2)
Female (n,%) 339, 56%
BMI 28.9 (5.8)
Obese (n, %) 214, 35%
WOMAC pain (0-100) 33.2 (17.6)
WOMAC function (0-100) 32.4 (18.2)
SF-12 PCS 41.3 (9.5)
SF-12 MCS 52.8 (10.0)
7-day Participant Diary Mean (sd)
Left knee pain (0-100) 34.1 (18.6)
Right knee pain 33.4 (19.3)
Left highest knee pain 47.2 (20.9)
Right highest knee pain 44.9 (21.1)
• Excellent 23 (4%)
• Very good 93 (16%)
• Good 210 (36%)
• Fair 234 (41%)
• Poor 17 (3%)
The correlation between WOMAC pain and physical function scores was
unexpectedly strong (r=0.80). Unsurprisingly, there was no correlation
between the SF-12 PCS and the SF-12 MCS score (r=-0.10).
There were meaningful correlations between the WOMAC scores (past 48
hours) and prospective Participant Diary daily pain (r=0.47 to 0.54) and
global assessment of arthritis scores (r=0.45 to 0.46). There were smaller
corrections between the SF-12 PCS and the Participant Diary daily pain
scores (r=-0.31 to -0.34) and little association between the SF-12 MCS and
the Participant Diary daily pain scores (r=-0.06 to -0.11).
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While the WOMAC pain and physical function scores indicated a mild to
moderate level of pain and disability over the past 48 hours, prospective
data collection (Participant Diary) detected higher levels of knee pain
when the highest score reported of the 7 day period was utilized (highest
7-day knee pain). Further, the prospective 7-day Participant Diary also
demonstrated almost half of the study participants (44%) with a mean
global assessment of their knees as only ‘fair’ or ‘poor’.
A simple Participant Diary requiring daily recording of knee pain speciﬁed
as ‘at its worst’ on a 11 point rating scale over one week may provide an
inexpensive, robust and responsive outcome measure in long term clinical
trials compared to retrospective reporting of pain (past 48 hours) but
without descriptive speciﬁcity.
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VALIDATION OF DIGITALIZED HEALTH STATUS QUESTIONNAIRES
FREQUENTLY USED IN THE MONITORING OF OSTEOARTHRITIS: A CROSS
SECTIONAL STUDY
H.R. Gudbergsen Sr.
The Parker Inst., Frederiksberg, Capital Region, Denmark
Purpose: To validate digitalized Health Status Questionnaires (HSQs) used
for sampling Patient Reported Outcomes for knee osteoarthritis (KOA) pa-
tients, employing newly developed freeware on touch screens. Furthermore
to examine the effect of patient characteristics on differences between
HSQ-versions.
Methods: Touch screen answers were compared to answers on paper
versions of the most commonly used HSQs in the clinical management of
KOA, and participants were recruited from an ongoing in-house KOA trial
(the CAROT-study; ClinicalTrials.Gov Identiﬁer: NCT00655941). 20 female
participants, mean age 67 (SD 7), completed KOOS, SF-36, ADL Taxonomy,
Physical Activity Scale, VAS pain, function and patient global and Pain
Detect, and the trial proﬁle ensured testing of only one HSQ at the time
in a repeated randomized cross-over design. The two HSQ versions (paper
and touch screen) were completed with a 5 min. interval and between
each HSQ patients had a 5 min. break. Mean values for each version,
mean differences (95% CI), pooled means, medians, median differences,
Minimal Important Differences and Spearman correlation coeﬃcients were
calculated for all HSQs including relevant subscales.
Results: Correlations between touch screen and paper version of SF-36
were 0.92 for the physical component summary scale and 0.81 for the
mental component summary scale. Similar correlations for KOOS ranged
from 0.88 to 0.98, and the other instruments were tested with comparable
results. When analysing mean and median differences we found no consis-
tent pattern in differences between the two measures, nor were there any
systematic patterns in the differences between HSQ-versions. No signiﬁcant
inﬂuence was observed of age, former computer experience or level of
education on differences between the two HSQ-versions. The participants
did not need further help or explanations when ﬁlling out questionnaires
on screen and found the process easier than ﬁlling in paper versions of the
questionnaire. 16 of 20 overall preferred the touch screen version.
Correlation between paper- and touch-screen versions
Paper version Spearmans Correlation Touch Screen
Coeﬃcient Version
KOOS 0.97 KOOS
VAS pain 0.89 VAS pain
VAS function 0.87 VAS function
VAS patient global 0.78 VAS patient global
SF-36Physical Component Summary Scale 0.92 SF-36Physical Component Summary Scale
SF-36Mental Component Summary Scale 0.81 SF-36Mental Component Summary Scale
Physical Activity Scale 0.84 Physical Activity Scale
Pain Detect1 0.97 Pain Detect1
Pain Detect2 0.96 Pain Detect2
Pain Detect3 0.95 Pain Detect3
Pain Detect4 0.86 Pain Detect4
Pain Detect5 0.88 Pain Detect5
Pain Detect6 0.91 Pain Detect6
ADL Taxonomia 0.95 ADL Taxonomia
Conclusions: The digitalized HSQs on touch screen gave statistically com-
parable results to answers given on a paper version of the same HSQs. Use
of electronic questionnaires gives a safer and more precise data collection
due to direct registration of answers, and implementation as well as use of
this freeware is feasible for patients
333
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FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOL
PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE
CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN
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J. Ashworth1
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Purpose: To summarize SF-36 and EQ-5D health survey results from four
15-week, double-blind phase 3 studies of tapentadol PR in patients with
osteoarthritis (OA) pain (NCT00421928 [OA study 1] and NCT00486811
[OA study 2]), low back pain (NCT00449176), and pain related to diabetic
peripheral neuropathy (DPN; NCT00455520).
Methods: In the OA and low back pain studies, patients received placebo,
tapentadol PR (100-250 mg bid), or oxycodone HCl controlled release (CR;
20-50 mg bid) during a 3-week titration period and a 12-week maintenance
period. In the DPN study, patients received tapentadol PR (100-250 mg bid)
during a 3-week open-label titration period; patients with at least a 1-point
improvement in pain intensity (11-point numerical rating scale [NRS])
were randomized to receive placebo or their optimal dose of tapentadol
PR (determined in the titration period) during a 12-week double-blind
maintenance period. SF-36 and EQ-5D health survey questionnaires were
used to assess health status. The SF-36 consists of 8 dimensions (physical
functioning, role-physical, bodily pain, general health, vitality, social func-
tioning, role-emotional, and mental health) measured on a 0 to 100 NRS
(0 = being in poor health to 100 = being in good health) and summarized
as physical component and mental component summaries. The EQ-5D con-
sists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression), which are measured using 3 possible levels (“no
problems,” “some problems,” and “extreme problems”) and summarized
